Review Article
Year: 2022 | Month: February | Volume: 9 | Issue: 2 | Pages: 425-431
DOI: https://doi.org/10.52403/ijrr.20220254
Monoclonal Antibody Therapy: Breakthrough in Migraine Preventive Therapy
I Made Oka Adnyana1, Faldi Yaputra1
1Department of Neurology, Faculty of Medicine, Universitas Udayana, Bali, Indonesia.
Corresponding Author: I Made Oka Adnyana (oka_adnyana@unud.ac.id)
ABSTRACT
Preventive medicine is appropriate for the majority of patients, including migraine patients, since migraine is considered a chronic condition that causes debilitating headaches that impair quality of life. Oral migraine preventive medications are available, but their use is restricted owing to their side effects and the fact that they are not specifically intended for migraine prevention. The currently available monoclonal antibodies (all have been approved by the Federal Drug Administration (FDA)) were developed specifically for the prevention of migraine and specifically targeted the CGRP peptide, which plays a critical role in the migraine mechanism. Thus, we discussed the breakthrough in migraine prevention in this article, with a particular emphasis on the role of monoclonal antibodies.
Keywords: migraine prevention, monoclonal antibodies, CGRP.
[PDF Full Text]